PURPOSE: This first-in-human study aimed to evaluate the radiation dosimetry and whole-body biodistribution of [ METHODS: [ RESULTS: [ CONCLUSION: This pilot study in ccRCC patients has demonstrated the safety, acceptable radiation dosimetry, favorable biodistribution, and exceptional tumor uptake of [ TRIAL REGISTRATION: This study was registered at ClinicalTrial.gov (ChiCTR2200058108) as NYPILOT on 29 March, 2022.